Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.

@article{Creager2011EffectOH,
  title={Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.},
  author={Mark A. Creager and Jeffrey W. Olin and Jill J. F. Belch and Gregory L. Moneta and Timothy D. Henry and Sanjay Rajagopalan and Brian Herb Annex and William Robert Hiatt},
  journal={Circulation},
  year={2011},
  volume={124 16},
  pages={1765-73}
}
BACKGROUND Hypoxia-inducible factor-1α (HIF-1α) is a transcriptional regulatory factor that orchestrates cellular responses to hypoxia. It increases collateral vessel growth and blood flow in models of hind-limb ischemia. This study tested whether intramuscular administration of Ad2/HIF-1α/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1α, improves walking time in patients with peripheral artery disease and intermittent claudication. METHODS AND… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…